Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ior-EPOCIM
- Development stage
- Phase 1
- Lead developer
- Center for Molecular Immunology
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
ior-EPOCIM is a recombinant human erythropoietin (rHuEPO) biosimilar developed and produced in Cuba. It is used primarily as an erythropoiesis stimulating agent to correct anemia, optimize hemoglobin levels, and reduce transfusion requirements in patients, with particular use in cancer patients undergoing chemotherapy or radiotherapy[2][5][1]. Mechanistically, ior-EPOCIM acts by binding to the erythropoietin receptor on hematopoietic progenitor cells in the bone marrow, stimulating proliferation and maturation of red blood cell precursors, thereby increasing erythrocyte (red blood cell) production. It is also being investigated for neuroprotective effects in Parkinson’s disease and other neurodegenerative disorders[3][7]. Clinical studies have shown ior-EPOCIM to be effective, well-tolerated, and generally safe, with adverse events mostly mild and typical for this drug class. It is officially approved for human use in Cuba and several other countries[3][7][4].
- Brand names
- ior®EPOCIMior-EPOCIM
- Other names
- Cuban recombinant human erythropoietinrHuEPO (ior-EPOCIM)
02
Targets
Erythropoietin Receptor
Beyond the preview
Go deeper on ior-EPOCIM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ior-EPOCIM.